2/21
02:04 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
2/20
03:50 pm
eprx
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
2/20
03:10 pm
eprx
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Low
Report
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
2/19
02:18 am
eprx
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
High
Report
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
2/18
04:01 pm
eprx
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Medium
Report
Eupraxia Pharmaceuticals Announces Proposed Public Offering
1/15
08:02 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
1/9
08:02 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Neutral
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
1/8
07:05 pm
eprx
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
1/8
09:53 am
eprx
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
High
Report
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
1/8
07:34 am
eprx
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
High
Report
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
12/13
01:10 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at
Wall
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at
Wall
12/12
05:52 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.